Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Benjamin M Snyder; Alex H Lion; Amy E Helvie; Mark S Marshall; Michael J Ferguson

doi:10.1002/ccr3.6779

Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Clin Case Rep. 2023 Jan 3;11(1):e6779. doi: 10.1002/ccr3.6779. eCollection 2023 Jan.

Authors

Benjamin M Snyder¹, Alex H Lion¹, Amy E Helvie², Mark S Marshall¹, Michael J Ferguson¹

Affiliations

¹ Department of Pediatrics Indiana University School of Medicine Indianapolis Indiana USA.
² Department of Pharmacy Riley Hospital for Children at IU Health Indianapolis Indiana USA.

Abstract

Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response.

Keywords: Ewing sarcoma; PNET; crizotinib; precision oncology.

Publication types

Case Reports